Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer

Friday, December 10, 2010 - 10:00 in Health & Medicine

The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial.

Read the whole article on Physorg

More from Physorg

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net